pentobarbital will lessen the extent or influence of pimavanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Avoid coadministration if at all possible. Monitor for lowered pimavanserin efficacy. A rise in pimavanserin dosage might be desired.
This content is offered for educational needs only and isn't intended for healthcare guidance, analysis, or cure. Critique our health care disclaimer.
Coadministration of zuranolone with other CNS depressants may boost impairment of psychomotor overall performance or CNS depressant results. If unavoidable, contemplate dose reduction. .
Contraindicated (one)pentobarbital will minimize the extent or result of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is responsible for the development and elimination of cariprazine's active metabolites.
pentobarbital will decrease the level or influence of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the level or result of stiripentol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If struggling to prevent coadministration of stiripentol with potent CYP3A4 inducers, improve stiripentol dose.
pentobarbital will lower the extent or impact of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lower the level or outcome of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will reduce the level or effect of cyclosporine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will minimize the level or outcome of naloxegol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Usage of naloxegol with powerful CYP3A4 inducers will not be advised
pentobarbital will minimize the extent or outcome of alosetron by influencing hepatic enzyme more info CYP2C9/ten metabolism. Minimal/Importance Not known.
pentobarbital will decrease the level or result of fedratinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Impact of coadministering a powerful CYP3A4 inducer with fedratinib has not been researched.
Warning when discontinuing CYP3A4 inducers that happen to be coadministered with hydrocodone; plasma concentrations of hydrocodone may maximize and can result in probably fatal respiratory depression
Estradiol valerate/dienogest should not be utilised for at least 28 days after discontinuation of the inducer due to risk of lowered contraceptive efficacy.